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Abstract 
Palliative care should be a component of COVID-19 management to relieve suffering, improve 
patient outcomes and save cost. We identified and appraised palliative care recommendations 
within COVID-19 management guidelines in Africa using rapid document analysis. All 
guidelines of any language published between December 2019 and May 2020 were retrieved 
through online search and email to in-country key contacts. We appraised the documents using 
African Palliative Care Association standards for providing quality palliative care. Fifty-five 
documents were retrieved from 29 out of 54 African countries. Fifteen documents from 15 
countries were included in the final analysis, of which eight countries have identifiable PC 
recommendations in their COVID-19 management guidelines. The other seven countries have 
statements of recommendations which are relevant to palliative care. Governments and 
policymakers in Africa must prioritise palliative care within case management guidelines to 











COVID-19 was declared a pandemic by the WHO within three months of its emergence.(1) The 
number of cases and deaths are escalating in African countries. As of 21 May 2020, 95,201 
cases and 2,997 deaths have been reported from all 54 African countries.(2)  
COVID-19 case fatality rates range from 0ꞏ35 to 11%.(3) Risk factors for severe illness and 
mortality in COVID-19 include being elderly, the presence of pre-existing health problems, 
multi-morbidities,(4) and being of black and ethnic minority heritage.(5) In addition to these, 
severity and case fatality patterns in Africa may also be influenced by the lowered immunity 
in individuals with existing and undiagnosed conditions such as HIV/AIDS, tuberculosis 
infections, respiratory, cardiovascular, and metabolic conditions. Approximately 14% of 
patients have been reported to have the severe form of the disease, and 0ꞏ16% to 5% needed 
intensive care admission to manage severe respiratory symptoms.(6, 7) Inadequately resourced 
health systems in Africa face challenges of providing needed critical care medications and 
mechanical ventilators for intensive care.(8)  
COVID-19 patients and their families report distressing multidimensional symptoms and 
concerns. These range from distressing physical symptoms such as fever, breathlessness, 
fatigue, cough;(9) psycho-social concerns, and spiritual /existential distress caused by the threat 
to survival, worry, and clinical uncertainty.(10) WHO recommendations for isolation means 
families and patients risk additional distress and poor access to social support.(10)  
Palliative care is a core component of Universal Health Coverage and is required by WHA73.3 
resolution as part of member state responses to COVID-19(11). However,	 the	 neglect	 of	palliative	 care	 among	 the	 dying	 and	 the	 resulting	 unnecessary	 serious	 health‐related	suffering	 is	 well	 established.(12,	 13)	 WHO’s omission of palliative care from COVID-19 
response plans has been highlighted.(14) Palliative care must be a component of COVID-19 case 
management to relieve suffering, improve outcomes for patients and their family members, and 
save costs.(15, 16) Within limited resources, palliative care teams are supporting complex 
decision making for patients with severe COVID-19 illness.(17) Evidence from previous fatal 
viral epidemics	demonstrates	that	hospice	and	palliative	care	play	essential	roles	including	
providing protocols for symptom management, training non-specialists, being involved in 
triage, and providing psychosocial and bereavement care.(18) 	 	
Given the low coverage of palliative care services and fragile health systems in Africa, health 
care professionals should be supported to deliver palliative care through clear comprehensive 
case management guidelines. This review aims to identify and critically appraise the palliative 
care recommendations within COVID-19 case management guidelines in Africa. The research 
questions were;  
a) Are palliative care recommendations present within COVID-19 case management guidelines 
in these countries?  
b) What are the specific palliative care recommendations?  
c) Are the palliative care recommendations adequate when compared to the African Palliative 
Care Association (APCA) standards for providing quality palliative care across Africa?  
Method 
Design 
We conducted a rapid document analysis using a systematic procedure to retrieve and analyse 
COVID-19 clinical case management guidelines from all 54 countries in Africa.  
Search Strategy 
We searched the Guidelines International Network database for specific guidelines for the 
management of COVID-19 cases from Africa. In addition, we searched online sources 
including government agencies and ministry of health websites. In situations where guidelines 
were not available online or where documents available do not meet our inclusion criteria, key 
contact persons (ministry of health official, leaders of national palliative care associations, or 
palliative care champions) were contacted to obtain these documents. The process was 
coordinated by the African Palliative Care Association (APCA),  the regional body that 
supports and coordinates the development and sustainability of palliative care. We emailed key 
contact persons in 39 countries.  
Inclusion Criteria  
We included guidelines for case management of COVID-19 published between December 
2019 and 10 May 2020, written in any language. Our search was restricted to Guidelines 
prepared by a national government ministry or nationally recognised government body tasked 
with this responsibility. We included only guidelines prepared by the government as we were 
interested in assessing whether the government is considering and prioritising palliative care 
in the delivery of care to COVID-19 patients. Where a country has more than one version of 
the guideline, the most recent version was used. 
Exclusion Criteria  
We excluded: guidelines that were regional or hospital-based; guidelines that were prepared by 
NGOs or national associations not commissioned by the government; High-level strategy 
documents focusing on National Preparedness and Response Plan; Opinion pieces, 
commentaries, communique and editorials.  
Data extraction (selection and coding) 
A data extraction sheet was designed, piloted, and used to extract the following variables: 1) 
characteristics of each guideline i.e. country, title, date, and version of the guidelines. 2) 
Verbatim palliative care recommendations and content using related terms such as supportive 
care, supportive treatment, supportive therapy, hospice care, and end of life care. OA and MAO 
reviewed and extracted all guidelines together. Any guideline for which inclusion was unclear 
was discussed with second reviewers (AO, EC, EN, and KN). AO, EC, EN and KN also 
conducted independent checking and verification of all extracted data so that data extracted 
from each guideline was reviewed by a second researcher, and any disagreement was 
adjudicated by a third reviewer (RH). Guidelines in french language were independently 
forward translated by official French speakers (HA and SB) and their translations were 
compared for consistency. 
Data Analysis 
We conducted a narrative synthesis of the extracted data. We analysed the palliative care-
related contents of the guidelines using content analysis. In order to grade adequacy of the 
palliative care recommendations, we developed a matrix based on Principle 2 of the APCA 
standards for providing quality palliative care across Africa (19). The APCA standards document 
was developed through wide consultation with service beneficiaries and providers to establish 
a framework for the development of evaluation and performance indicators to facilitate 
palliative care programme improvement and development across Africa. The document 
contains 37 standard statements grouped under four main principles including organisational 
management, holistic care provision, children’s palliative care, education and training, and 
Research and Management of Information.(19)  As we were reviewing case management 
guidelines and protocols, we assessed adequacy with respect to Principle 2 (Holistic Care 
provision) which has 17 standard themes (Table 1). This principle is most relevant to the direct 
patient and family care and support. 
OA and MAO independently graded and checked the adequacy of the COVID-19 case 
management guidelines assigning fully met, partially met, not met, or not applicable. EN, EC, 
AO and KN verified the grading and any disagreement was resolved through discussion. ‘Fully 
met’ was assigned when a recommendation in a guideline comprehensively addresses the 
APCA summary statement for a standard. ‘Partially met’ was assigned when a guideline’s 
recommendation addressed some or part of the quality standard summary statement. ‘Not met’ 
was assigned when a guideline’s recommendation was deemed not to have met any aspect of 
the quality standard. Recommendations were assessed as ‘Not applicable’ where we could not 
assess a standard due to the complexity of the criteria and where it is not directly involving 
patient care. 
Role of the funding source 
No funding was declared for this study. 
Results 
Out of the 54 African countries, 31 documents from 14 countries (Nigeria, South Africa, 
Ghana, Libya, Tunisia, Chad, Cameroun, Djibouti, Equatorial Guinea, Eritrea, Morocco, Cote 
D’Ivoire, Cape Verde, and Algeria) were retrieved through online searches and 23 documents 
from responses of 16 Key contact persons (Cote D’Ivoire, Togo, Mozambique, Namibia, The 
Gambia, Botswana, Tanzania, Uganda, Burundi, Malawi, Kenya, Zimbabwe, Ethiopia, 
Eswatini, South Sudan, and Sudan). Two responded with no document to provide (Mauritius) 
or referred us to their website for documents (Rwanda).  We had no response from the 
remaining 21 countries after two reminders were sent and we could not identify a key contact 
in Niger and Sao tome and Principe where. In total, we retrieved 55 documents from 29 
countries. Figure 1 shows the process of retrieval and selection of documents. We included 15 
documents (11 in English and four in French) from 15 countries (Algeria, Botswana, Cote 
D’Ivoire, Eswatini, Ethiopia, Gambia, Morocco, Namibia, Nigeria, South Africa, South Sudan, 
Sudan, Tanzania, Togo, and Uganda) in this review. 40 documents were excluded with reasons 
indicated in Figure 1: PRISMA flow chart 
Data extracted from the guidelines are shown in Supplementary File 1. Of the 15 countries’ 
guidelines reviewed, only eight countries (Algeria, Botswana, Namibia, South Africa, Sudan, 
South Sudan, Togo, and Uganda) had identifiable inclusion of palliative care or supportive 
care. Other countries (Eswatini, Ethiopia, Cote D’Ivoire, Gambia, Morocco, Nigeria, and 
Tanzania) have statements of recommendations which are relevant to palliative care within the 
document.  
All 15 guidelines proposed recommendations on the management of physical symptoms, 
especially managing breathlessness with oxygen and nebulizer or bronchodilators, secondary 
bacterial infections with antibiotics, and fever with paracetamol. South Sudan and Tanzania’s 
guidelines were the only ones to provide a set of comprehensive recommendations on 
psychosocial support and ensuring effective communication with patients and families. 
Tanzania also recommended psychosocial support for healthcare professionals; Cote D’Ivoire, 
Ethiopia and Eswatini recommended some level of psychosocial support while Namibia and 
Uganda mentioned psychosocial support only when referring to care of pregnant women with 
COVID-19. Further details on the palliative care recommendations proposed in the guidelines 
are in the extraction table (see Supplementary File 1). 
 
Figure 1: PRISMA flow chart 
Reference to information and communication was only present within Cote D’Ivoire, Ethiopia, 
South Sudan, Sudan, Tanzania, Uganda, and Eswatini guidelines. Recommendations on 
meeting spiritual needs were only available in Ethiopia and South Sudan guidelines. In 
addition, only guidelines from South Sudan, Eswatini, Ethiopia, and Uganda have 
recommendations on decision making and choice in care; while only guidelines from South 
Sudan, Eswatini, Ethiopia, Tanzania, and Uganda, made recommendations on supporting 
families whose relations have severe COVID-19 disease. 
Table 1 reveals the adequacy of the palliative care recommendations within the guidelines and 
protocols when evaluated using standard statements listed in principle 2 of the APCA standards 
for providing quality palliative care. The majority of the standards were not met. Standards 2.1 
(Planning and coordination of care), 2.2 (Access to Specialist Palliative care), 2.4 (Pain and 
symptom Management), 2.6 (Management of Medications), 2.11 (Care for special needs 
populations), and 2.17 (Providing support to care providers) were partially met by the majority 
of the guidelines and only standard 2.5 (Management of opportunistic infections) was fully met 
by 14 out of 15 guidelines. Standard 2.15 (Clinical Supervision) was deemed not applicable 
and the remaining standards were unmet in the majority of the countries. 
Table 1: The adequacy of the guidelines against the APCA standards for quality palliative care in 15 
countries 
Countries 








































in palliative care 
2.11: C
are for special needs 
populations 
2.12: End-of-life care 
2.13: G
rief, loss and 
bereavem
ent care in adults 
2.14: Ethical care, hum
an 
rights and legal support 
2.15: C
linical Supervision 
2.16:  Inter-disciplinary Team
 
2.17:   Providing support to 
care providers 
Algeria + x x + ++ + x x x x x x x x N/A x + 
Botswana + + x + ++ + x x x + + x x x N/A x + 
Cote 
D’Ivoire 
+ + + + x + + x x x + x x x N/A + + 
Ethiopia + + ++ + ++ + + + + x + + + + N/A x + 
The Gambia + + x + ++ + + x x x + x x x N/A x + 
Morocco + x x + ++ + x x x x x x x x N/A x + 
Namibia + + x + ++ + + x x x + x x x N/A x + 
Nigeria + x x + ++ + x x x + + x x x N/A x + 
South Africa + + x + ++ + x x x x + + x x N/A x + 
South Sudan ++ ++ ++ ++ ++ + ++ + + + ++ x x + N/A ++ + 
Sudan + + + + ++ + x x x + + x x x N/A x + 
Eswatini + x + + ++ + + x + x + + x + N/A x + 
Tanzania + + ++ + ++ + ++ x + x + ++ ++ x N/A ++ ++ 
Togo + + x + ++ + x x x + x x x x N/A x + 
Uganda + + + + ++ + + x x x ++ x x + N/A ++ + 
Legend 
++ - Fully met 
+ - Partially Met 
x- Not Met 




Our study set out to critically appraise the case management guidelines for COVID-19 in Africa 
for their palliative care content and evaluate the adequacy of this against APCA standards for 
quality palliative care provision across Africa. 
The majority of the countries with specific sections on palliative care are in Southern and 
Eastern Africa. This reflects the development of palliative care in these countries with strong 
advocacy networks and well-developed services and national policies.(20) Also, these countries 
named their treatment and therapeutic management sections supportive therapy or supportive 
treatment to recognize the absence of curative treatment for COVID-19 as against other 
countries. 
While some case management documents made recommendations for some symptoms, there 
were no recommendations on other palliative care problems that may accompany 
breathlessness in COVID-19 such as delirium, anxiety, and cough.(21) Also, except for 
guidelines in South Sudan, Ethiopia, Eswatini, and Uganda, there were no clear 
recommendations for giving patients and families choices regarding care decisions such as the 
use of mechanical ventilation. In a continent where healthcare delivery has been known to be 
paternalistic (22) and palliative care training and education are limited,(20) there is need for 
explicit recommendations on shared decision making, fostering autonomy of choice, providing 
psychosocial care, patient-centred referrals to palliative care, and encouraging adequate 
communication with the patient and families at a time of high anxiety. 
The importance of religious and cultural practices around dying in contributing to the spiritual 
needs of patients and families have been documented.(23) However, most of the guidelines we 
reviewed did not meet the standards of spiritual and cultural care (2.8 and 2.9 respectively). 
While there were sections on managing dead bodies in recommendations from some countries, 
caring for the dying is omitted in  all the case management guidelines. This suggests a lack of 
priority on supporting the dying phase to reduce distress and suffering.(12) This might also be 
indicative of the pervasive reticence and taboos around discussing the death and dying in 
African cultures.(24)  
There are limitations which may affect the interpretation of our findings. The wording of the 
APCA standard influenced our analysis. The specific wordings within the APCA standard is 
arguably HIV/AIDS and cancer-focused. For example, standard 2.5 heading and summary 
statement read, “Management of Opportunistic Infections (OIs): Appropriate management of 
opportunistic infections, including tuberculosis (TB), improves the quality of life among 
people living with HIV and AIDS, and those with other life-threatening illness.”  We applied 
this by looking at treatment recommendations for secondary/ superimposed bacterial 
pneumonia infections within the context of COVID-19. We acknowledge that the HIV/AIDS 
pandemic and cancer have largely influenced the development of palliative care in Africa. 
However, there is a wider debate that people with other progressive serious illnesses aside from 
HIV/AIDS and cancer have poor access to palliative care in Africa. This highlights the need 
for APCA to review and expand the standards to make it more inclusive within the context of 
wider serious health-related suffering.(25) Our findings are also based on documents that we 
were able to retrieve online or from key contact persons. We are aware that there might be 
other guidelines from government and NGOs which address some of the areas that we 
identified as weak. In addition, we only did forward translation for guidelines in the French 
language; therefore some meanings might have been lost in translation. 
Furthermore, we applied standard 2.6 (the management of medications) by considering oxygen 
and other medication recommended in majority of the guidelines as serving palliative care or 
supportive therapy purposes. In the context of poorly resourced health systems in Africa, even 
oxygen for the management of breathlessness (which many of the guidelines recommended) 
may be unavailable, and as such might require rationing. In addition, the detailed criteria for 
this standard are related to medications commonly used in palliative care such as opioids which 
require proper training to prescribe and use. Therefore, clear guidance must also be 
recommended on the use of opioids as an additional line of management for breathlessness in 
patients dying of COVID-19 (21) and systems must be put in place to ensure their availability. 
Like the HIV/AIDS pandemic before it, the COVID-19 pandemic might catalyse the 
development of palliative care in Africa to meet the needs of the non-COVID population. The 
focus of palliative care is on managing serious health-related suffering (12, 25) and this is the 
only type of care we can offer patients with severe COVID-19 disease while we conduct further 
research into developing vaccines and curative treatment. There is extensive palliative care 
evidence on approaches to managing serious health-related suffering. It is therefore imperative 
for governments, policymakers, and stakeholders in Africa to prioritise the role of palliative 
care in the management of patients with COVID-19.  
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SUPPLEMENTARY FILE 1:  Palliative care recommendations in included Guidelines  
Table 1: Palliative Care Recommendations within the included guidelines 
Country  Title, date, 
version and 







Verbatim palliative care 
recommendations 
If NO 
Other recommendations that are 
palliative in approach 
Principle 2: Holistic Care Provision 
2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 
Algeria  Preparation and 
Response Plan 




No date and no 
version 
Yes 2- Symptomatic treatment (Pg105-
107) 
a) Oxygen therapy: (2.4) 
Objective: Obtain an oxygen 
saturation greater than or equal to 
92%. (2.1) 
The modes of administration of O2 
vary according to the administered 
rates: 
• Oxygen glasses: flow between 0·5 to 
5l / min; 
• Oxygen mask: flow between 5 to 8 l 
/ min; 
• Oxygen mask with reserve above 8l / 
min (only in the absence of a 
respirator) 
b) Mechanical ventilation: If not 
improved after 1 to 2 hours 
3- Associated treatment: 
- Adapted vascular filling 
- Vasopressors: Noradrenaline, 
Adrenaline, Dobutamine 
- No broad spectrum antibiotic 
- Systematic antibiotic therapy in the 
case of ARDS or if there are foci of 
alveolar condensation. We will 
prescribe a 3rd generation 
cephalosporin associated with a 
quinolone; (2.1, 2.5) 











































































4- Specific treatment 
For all patients with a moderate form, 
a form with pneumonia and / or a 
severe form suspected of Covid-19 
infection: it will be prescribed, 
In the absence of contraindications 
and under medical supervision: 
1st intention: Chloroquine: 500 mg 
twice a day for 5 to 7 days Or 
Hydroxychloroquine: 200 mg, 3 times 
a day for 10 days 
2nd intention: Lopinavir / ritonavir: 
(tablet 200/50 mg) at a rate of 2 
tablets, twice a day respecting the 
rules of use for 5 to 7 days Or 
Atazanavir: 300 mg / day for 2 weeks. 










Version: 1.0  
2nd April 2020 
Yes Early supportive therapy in 




• Oxygen therapy is likely to be the 
single most effective supportive 
measure in COVID-19 patients 
overall. (2.4) 
• Give supplemental oxygen therapy 
immediately to patients with low 
oxygen saturation. (2.4) 
• Start oxygen therapy if the Sp02 falls 
below 90% in adults and children or if 
below 92% in pregnant women(15). 
(2.1, 2.4) 
• Once commenced, aim for an Sp02 
of 92-96%. 
• Do not over oxygenate as this is 
associated with harm. 
• Titrate oxygen therapy up and down 
to reach targets by means of nasal 















































































mask with reservoir bag, as 
appropriate.  
 
Fluids (page 20) 
• Use conservative fluid management 
in patients with SARI when there is no 
evidence of shock. (2.4) 
• Aggressive fluid resuscitation may 
lead to pulmonary oedema and worsen 
oxygenation. 
• In resuscitation for septic shock in 
adults, give 250–500 mL crystalloid 
fluid (normal saline or Ringer’s 
Lactate) as rapid bolus in first 15–30 
minutes and reassess for signs of fluid 
overload after each bolus. 
 
Vasoactive Agents (page 21) 
• Aim for a mean arterial pressure of 
60-65 mmHg. 
• Only start vasopressors once 
confirming that patients are fluid 
replete.(2.1, 2.4) 
• We suggest using norepinephrine as 
first line vasoactive agent. If 
unavailable we suggest using 
vasopressin or epinephrine. 
• If signs of poor perfusion and 
cardiac dysfunction persist despite 
achieving MAP target with fluids and 
vasopressors, consider an inotrope 
such as dobutamine. 
 
Antibiotics (page 21) 
• If clinical suspicion for co-infection 
exists, consider empirical  
antimicrobials to treat copathogens 
causing the syndrome. (2.5) 
• Treat suspected or confirmed 
pneumonia with: 
o Co-amoxiclav 625mg PO TDS or 
1·2gram IV TDS for seven days 
AND 
o Azithromycin 500mg OD/IV for 
seven days 
 
Specific therapies (page 21) 
• Ensure patients have thrombo-
prophylaxis prescribed if not 
contraindicated. (2.1, 2.6) 
• Do not routinely give systemic 
corticosteroids for treatment of 
COVID- 19 unless they are indicated 
for another reason(17, 18). 
• There is no current evidence from 
RCTs to recommend any specific anti-
nCoV treatment for patients with 
suspected or confirmed COVID-19 
infection. 
• Do not therefore give hydroxy- 
chloroquine or chloroquine to patients. 
• If pneumocystis pneumonia is 
strongly suspected start high dose 
CTX and steroids, if necessary. 
• Consider a blood transfusion if the 
Hb < 70 g/L (7·0g/dL) in the absence 
of extenuating circumstances such as 
myocardial infarction, severe 
hypoxaemia or acute haemorrhage. 
Targeting higher Hb thresholds (>90-
100 g/L) does not lead to better 
outcomes in patients with sepsis. 
Give early enteral nutrition (within 48 
hours of admission). 2.10 
Cote 
D’Ivoire 





(SIPP) pour la 
No  Care and management pg 17-19 
Whatever the clinical form, the care 
must necessarily include personnel 
protection measures, an appropriate 
assessment and a consistent 
















































































prise en charge 
de la COVID- 
 
19Version du 
16 avril 2020 
- Staff protection measure (2.17) 
- Therapeutic attitude (2.7, 2.3) 
- psychological support (2.7) 
- oxygen therapy if SaO2 ≤ 95% (2.1, 
2.4) 
- treatment of symptoms (fever, runny 
nose, abundant drink) (2.4) 
- patient and family education (2.3, 
2.1, 2.17): barrier measures, establish 
telephone connection daily (2.7), daily 
temperature monitoring, ban visits 
- Transfer of the patient to the 
intensive care unit (2.2) 
- Assessment to be made in the care 
unit (2.1) 
Treatment of special cases (2.11) 
Management must be 
multidisciplinary, (2.16) particularly 
for: 
o children 
o elderly subjects 
o pregnant women 
o subjects with disabilities 
 
All basic asthma and COPD 
treatmentsshould be continued 
(corticosteroids inhaled, possibly 
associated with other molecules 
(LABA, LAMA, montelukast, oral 
corticosteroid therapy at minimum 
effective dose ...) (2.6) 










General principle of clinical 
mangement for COVID-19 (page 40 
to 41)                          ▪Underlying 
/chronic diseases should be identified 
as early as possible with detailed 
history from patient, close family 
members or friends. (2.1.) 
▪Drug interactions, adverse effects of 





















































































considered during managing the 
patient with COVID-19. (2.6) 
▪Patient care should be with respect 
and dignity which include: 
respect/dignity, medical support, 
food/water, and information. (2.14, 
2.3) 
▪ Give supplemental oxygen therapy 
to patients with low oxygen 
saturation: (2.4) 
▪No proven anti-viral therapy or 
vaccine against COVID-19 so far 
necessitating supportive care for 
specific symptoms. (2.4) 
▪Provide symptomatic therapies with 
antipyretic /analgesic (2.4) 
▪In COVID 19 superimposed bacterial 
infection is common and to treat all 
likely pathogens antibiotics 
administration (2.5) 
▪Notify the family and provide grief 
counseling according to the ethical 
standards (2.3, 2.13, 2.14, 2.17) 
▪Close families should be allowed to 
see the body after tubes removed and 
wound sites dressed under strict IP 
precautions (2.13) 
▪Religious rituals are to be conducted 
at the mortuary but coffin should not 
be opened (2.8, 2.13) 
▪Individuals are treated with respect 
and dignity. (2.14, 2.3) 
▪The final decision about which 
medical interventions to accept, if any, 
belongs to the patient. (2.3, 2.14, 2.1) 
▪Patients should also be allowed to 
access family members and significant 
others through 
phone. (2.3, 2.17, 2.7) 
▪Information on patient‘s condition 
should be communicated to their 
family regularly and upon request by 
the treating physician. (2.3) 
▪Determine methods for patient/family 
information provision including 
alternate languages/interpretive 
services. (2.3, 2.14) 
▪Ensure regular and timely 
communication with and feedback to 
family, friends or other relations of 
patients who are admitted regarding 
their health status (2.3) 
▪Make sure to speak to patients in a 
tone that is customary for providing 
comfort and building trust when 
speaking to family or community 
members. (2.3) 
▪Do not make promises regarding if a 
family member will recover – this 
may lead to mistrust if the patient does 
not recover. (2.3, 2.12, 2.13, 2.14) 
▪Allow family members to view 
patients or provide for basic needs of 
their family members (e.g. clean 
clothes, food, etc.) as per appropriate 
IPC protocols. (2.7, ) 
▪If a patient dies, be sure to inform the 
family as soon as possible and calmly 
explain the process of body treatment 
(burial ground or cremation options as 












*Paracetamol 1 g tds PO for 48 hrs, 
then review (2.4). 
*Rehydrate with IV Fluids N/saline 
with 5% Dextrose IL over 8 hrs in 
adults for 24 hrs then review (2.4). 
*Oral Antibiotics if suspected 














































































Azithromycin 500 mg daily orally for 
3 days (2.5). 
*Closely monitor patients with 
moderate COVID-19 disease for early 
signs of clinical deterioration, such as 
rapidly progressive respiratory failure 
and sepsis and respond immediately 
with supportive care interventions. 
The ability to identify, assess and 
escalate care for deteriorating 
hospitalised COVID-19 patients 
appropriately can make some 
difference in our outcomes. Use of the 
MEWS Score (Modified Early 
Warning Score) can identify patients 
who are deteriorating or at risk of 
deteriorating to ensure timely 
assessment and intervention (2.1, 2.2, 
2.4). 
* IV Antibiotics if suspected 
secondary bacterial infection, IV 
Ceftriaxone 2g Daily for 5 days 
initially, then review. If suspected 
CAP, follow with macrolide, 
Azithromycin 500 mg daily orally for 
3 days (2.5, 2.6). 
* Oxygen therapy via fixed oxygen 
delivery masks to keep Sp02 between 
95-96% if no COPD . If COPD, keep 
SpO2 between 88-92%  
If a patient is failing to respond to 
oxygen delivered via a face mask, 
then consider non-invasive ventilatory 
(NIV) support if persistent hypoxia 
(SpO2 < 92%) despite high flow 
oxygen  
Check Arterial Blood Gas (ABG) if 
available.  
Initiate oxygen therapy at 5 L/min and 
titrate flow rates to reach target SpO2 
≥ 93% during resuscitation; or use 
face mask with reservoir bag (at 10–
15 L/min) if patient in critical 
condition. Once patient is stable, the 
target is > 90% SpO2 in non-pregnant 
adults and ≥ 92–95% in pregnant 
patients. Oxygen should be turned 
down if saturations are consistently 
99-100%) (2.1, 2.4).   
* Maintain the airway and give 
oxygen therapy during resuscitation to 
target SpO2 ≥ 94%; otherwise, the 
target SpO2 is ≥ 90% (25).   
 *The ability to identify, assess and 
escalate care for deteriorating 
hospitalised COVID-19 patients 
appropriately can make some 
difference in our outcomes. Use of the 
MEWS Score (Modified Early 
Warning Score) can identify patients 
who are deteriorating or at risk of 
deteriorating to ensure timely 
assessment and intervention. (2.1, 2.2)  
 *Treat any associated co-morbidity 
appropriately  
 
Care for pregnant women and 
neonates 
* Pregnant women should be treated 
with supportive therapies as described 
above. So far, there is no evidence on 
mother-to-child transmission of 
COVID-19 when infection is in the 
third trimester. There is no evidence 
that pregnant women present with 
different signs or symptoms or are at 
higher risk of severe illness (2.1, 
2.11).   
* Encourage and support mother and 
baby to be together. Consider 
separating mother and baby partially 
or completely (e.g. discharging baby 
home before unwell mother) only after 
taking into account limited local 
capacity, disease severity, 
psychological wellbeing, parental 
preferences, if method exists to feed 
baby e.g. bottle or cup feeding (2.1, 
2.7, 2.11).  
*Provide oxygen via nasal cannula to 
maintain SPO2 >90% (>88% for 
preterm neonates).  
Avoid potentially aerosolizing 
techniques if possible (E.g. suctioning, 
CPAP). If a neonate requires CPAP 
for clinical reasons (Silverman score 
≥4 or persistently hypoxic despite 
oxygen (2.11).   
* Provide routine maintenance fluids 
according to age and weight, as per 
standard care. Provide expressed 
breast milk as soon as possible as per 
standard neonatal care including use 
of gastric tubes and cup feeding (2.4, 
2.11).  
 
Children with COVID-19 
*Older children and adolescents 
should receive oxygen via a face 
mask. Face masks with reservoir bags 
should be reserved for those with 
severe disease to deliver 10 – 15 
L/min. Head boxes or other devices to 
maximise oxygen delivery should be 
used where possible.  
CPAP is not currently available for 
children with confirmed or suspected 
COVID-19 (2.4, 2.11).  
*Children with asthma should be 
treated as usual but with salbutamol 
given via a spacer rather than 
nebulized to reduce the risk of 
aerosolization of COVID-19. Oral 
steroids should be used as normal for 
children with asthma (2.1, 2.4, 2.11). 
Morocco  Protocole de 



















6. Therapeutic protocol (pg3) 
Antibiotic therapy: Not systematic, 
indicated if secondary bacterial 
infection. (2.1, 2.5) 
Amoxicillin + clavulanic acid, 3g per 
day 
Or 
Moxifloxacin 400mg / d in one 
Or 
Levofloxacione 500 mg / day in a 
single dose 
Nebulization: use if necessary, with 
the necessary precautions to prevent 





















































































Yes Patients with severe COVID-19 (page 
47) 
Oxygen therapy and monitoring 
*Give supplemental oxygen therapy 
immediately to patients with SARI 
and respiratory distress, hypoxaemia 
or shock and target > 94% and ≥ 92–
95% in pregnant patients (2.4).  
*Closely monitor patients with 
COVID-19 for signs of clinical 
deterioration, such as rapidly 
progressive respiratory failure and 
sepsis and respond immediately with 
supportive care interventions (2.1, 
2.4).  
*Application of timely, effective and 















































































cornerstone of therapy for patients that 
develop severe manifestations of 
COVID-19 (2.1, 2.2, 2.4).  
*Understand the patient’s co-morbid 
condition(s) to tailor the management 
of critical illness (2.1, 2.5)  
*Monitor for drug-drug interactions 
(2.6).  
*Use conservative fluid management 
in patients with SARI when there is no 
evidence of shock (2.1, 2.4).  
 
Treatment of co-infections (page 47) 
*Give empiric antimicrobials to treat 
all likely pathogens causing SARI and 
sepsis as soon as possible, within 1 
hour of initial patient assessment for 
patients with sepsis (2.4, 2.5).  
*Empiric therapy should be de-
escalated based on microbiology 
results and clinical judgment (2.1).  
 
Acute Respiratory Distress Syndrome 
(ARDS) (page 47) 
*Recognize severe hypoxemic 
respiratory failure when a patient with 
respiratory distress is failing standard 
oxygen therapy and prepare to provide 
advanced oxygen/ventilatory support 
(2.1, 2.4).  
*Endotracheal intubation should be 
performed by a trained and 
experienced provider using airborne 
precautions (2.1, 2.4).  
*Rapid sequence intubation is 
appropriate after an airway assessment 
that identifies no signs of difficult 
intubation (2.1, 2.4).  
*Aim for an initial tidal volume of 
6mg/kg.16 Tidal volume up to 8 ml/kg 
predicted body weight is allowed if 
undesirable side effects occur (e.g. 
dyssynchrony, pH <7·15) (2.1, 2.4).   
*Use lower inspiratory pressures 
(plateau pressure <30 cmH2O). (2.1, 
2.4).  
*Hypercapnia is permitted if meeting 
the pH goal of 7·30-7·45 (2.1, 2.4).   
*Application of prone ventilation >12 
hours a day is strongly recommended 
for patients with pressures (2.1, 2.4) 
*In patients with moderate or severe 
ARDS, moderately higher PEEP 
instead of lower PEEP is 16 targets 
(2.1, 2.4).   
*In patients with moderate-severe 
ARDS (PaO2/FiO2 <150), 
neuromuscular blockade by 
continuous infusion should not be 
routinely used (2.1, 2.4). 
  
Septic Shock (page 48) 
*Recognize septic shock in adults 
when infection is suspected or 
confirmed AND vasopressors are 
needed to maintain mean arterial 
pressure (MAP) ≥ 65 mmHg AND 
lactate is ≥ 2 mmol/L, in absence of 
hypovolemia (2.1, 2.4).  
*Recognize septic shock in children 
with any hypotension (systolic blood 
pressure [SBP] < 5th centile or > 2 SD 
below normal for age) or two or more 
of the following:  
o Altered mental state 
o Tachycardia or bradycardia (HR < 
90 bpm or > 160 bpm in infants and 
HR < 70 bpm or > 150 bpm in 
children) 
o Prolonged capillary refill (> 2 sec) 
or feeble pulses; tachypnoea; mottled 
or cold skin or petechial or purpuric 
rash 
o Increased lactate; oliguria; 
hyperthermia or hypothermia (2.1, 
2.4).  
 
Pregnant women with COVID-19 
(page 48) 
*Considering asymptomatic 
transmission of COVID-19 may be 
possible in pregnant or recently 
pregnant women, as with the general 
population all women with 
epidemiologic history of contact 
should be carefully monitored (2.1, 
2.4, 2.11).  
*Pregnant women with a suspected, 
probable or confirmed COVID-19 
infection, including women who may 
need to spend time in isolation with 
obstetric, foetal medicine and neonatal 
care, as well as mental health and 
psychosocial support, with readiness 
to care for maternal and neonatal 
complications (2.1, 2.4, 2.7, 2.2.11).  
*Currently no evidence that pregnant 
women present with increased risk of 
severe illness or fetal compromise.  
*Pregnant and recently pregnant 
women who have recovered from 
COVID-19 should be enabled and 
encouraged to attend routine antenatal 
or postpartum care as appropriate. 
(2.1, 2.11)  
 
Infants and Mothers with COVID-19 
(page 48) 
*Infants born to mothers with 
suspected, probable or confirmed 
COVID-19 infection, should be fed 
according to standard infant feeding 
guidelines, while applying necessary 
precautions for IPC (2.1, 2.1, 2.11).  
*As with all confirmed or suspected 
COVID-19 cases, symptomatic 
mothers who are breastfeeding or 
practicing skin-to-skin contact or 
kangaroo mother care should practise 
respiratory hygiene, including during 
feeding (for example, use of a medical 
mask when near a child if with 
respiratory symptoms), perform hand 
hygiene before and after contact with 
the child, and routinely clean and 
disinfect surfaces which the 
symptomatic mother has been in 
contact with (2.1, 2.4, 2.11).  
*Breastfeeding counselling, basic 
psychosocial support and practical 
feeding support should be provided to 
all pregnant women and mothers with 
infants and young children, whether 
they or their infants and young 
children have suspected or confirmed 
COVID- 19 (2.1, 2.4, 2.7, 2.11).  
*In situations when severe illness in a 
mother due to COVID-19 or other 
complications prevent her from caring 
for her infant or prevent her from 
continuing direct breastfeeding, 
mothers should be encouraged and 
supported to express milk, and safely 
provide breastmilk to the infant, while 
applying appropriate IPC measures 
(2.1, 2.4, 2.11) 




Clinical management of COVID-19 










































Version 1 14 
March 2020 
RR >30/min, or SpO2 < 90% (<92% 
in children). (2.4, 2.11) 
▪Provide further supportive care as 
appropriate (2.4) 
▪Continue supportive care as 
appropriate (2.4) 
▪Ensure optimal oxygenation (2.4) 
▪Use broad spectrum antibiotics based 
on local epidemiology (2.5) 
▪Early supportive therapy and 
monitoring is recommended for a 
favourable outcome (2.1, 2.4) 
▪Manage symptoms fever, cough, sore 
throat, nasal congestion, malaise, 
headache and muscle pain – with 
antipyretics, cough medicine, rest, 
(2.4) 
▪Provision of supplemental oxygen 
therapy is a hallmark of treatment for 
severe cases (2.4) 
▪Supplemental oxygen therapy (2.4) 
▪Commence High-Flow Nasal Oxygen 
(HFNO) or Non-Invasive Ventilation 
(NIV) at 10-15L/ minutes (2.4) 
▪Give supportive therapy as the need 
arises. (2.4) 
▪Maintain nutrition support (enteral or 
parental as indicated) (2.4) 
▪Give oxygen therapy (2.4) 
▪Give supportive therapy as need 
arises to ensure sufficient fluid and 
electrolyte balance (2.4) 
▪Maintain nutrition support (enteral or 
parental as indicated) (2.4) 
▪Supportive therapies as generically 
described, taking into consideration, 
















































Yes 4.2 Early supportive therapy in 









































Version 3 (27th 
March 2020) 
11)                                                         
▪Give supplemental oxygen therapy 
immediately to patients with low 
oxygen saturation. (2.4) 
• Oxygen therapy is likely to be the 
single most effective supportive 
measure in COVID-19 patients 
overall. Target SpO2 ≥90% in non-
pregnant adults and SpO2 ≥92% in 
pregnant patients.7 Children with 
emergency signs (obstructed or absent 
breathing, severe respiratory distress, 
central cyanosis, shock, coma or 
convulsions) should receive oxygen 
therapy during resuscitation to target 
SpO2 ≥94%; otherwise, the target 
SpO2 is ≥92%. (2.1, 2.5) 
• Titrate oxygen therapy up and down 
to reach targets by means of nasal 
cannula, a simple face mask or a face 
mask with reservoir bag, as 
appropriate: (2.1, 2.5) 
▪Use conservative fluid management 
in patients with COVID-19 when 
there is no evidence of shock. (2.4) 
▪Aggressive fluid resuscitation may 
worsen oxygenation, especially in 
settings where there is limited 
availability of mechanical ventilation. 
▪If a clinical suspicion for co-infection 
exists, consider empiric antimicrobials 
to treat copathogens 
causing the syndrome, particularly in 
severe cases. This may include 
conventional and atypical bacterial 
pathogens, influenza and PJP (see 
section 3.3 above). (2.1, 2.5) 
▪Closely monitor patients with SARI 













































progressive respiratory failure and 
sepsis, and apply supportive care 
interventions immediately. (2.1, 2.2, 
2.4) 




South Sudan  
 
Version 1, 2020 
Yes Management for Severe Illnesses 
(pages 10-13) 
The aim is to provide early optimized 
supportive care and monitoring (2.2).  
 
Oxygen therapy and monitoring  2.4, 
2.6 
*For clients presenting with 
respiratory distress, hypoxaemia or 
shock, providing supplemental oxygen 
therapy immediately is the hallmark of 
care for severe illnesses. 
*For Adults/Adolescents presenting 
with emergency signs such as 
obstructed or absent breathing, severe 
respiratory distress, central cyanosis, 
shock, coma or convulsions should 
receive airway management and 
oxygen therapy during resuscitation to 
reach a target of > 90% SpO2 in non- 
pregnant adults and ≥ 92–95% in 
pregnant patients.  
*Initiate oxygen therapy at 5 L/min 
and titrate flow rates to reach target 
SpO2 ≥ 93% during resuscitation;  
*For patients in critical condition and 
face mask with reservoir bag is 
available, provide oxygen therapy at 
10–15 L/min (2.1, 2.4) 
*For children presenting with 
emergency signs (obstructed or absent 
breathing, severe respiratory distress, 
central cyanosis, shock, coma or 
convulsions) should receive airway 
management and oxygen therapy 













































































of SpO2 ≥ 94%. Use of nasal prongs 
or nasal cannula is preferred in young 
children, as it may be better tolerated  
*Perform Haematology and 
biochemistry laboratory testing, and 
ECG where available at admission and 
as clinically indicated to monitor for 
complications, such as acute liver 
injury, acute kidney injury, acute 
cardiac injury or shock.  
*All patient must be closely 
monitored for signs of clinical 
deterioration, such as rapidly 
progressive respiratory failure and 
sepsis and respond immediately with 
supportive care interventions. 
*Remember application of timely, 
effective and safe supportive therapies 
is the cornerstone of therapy for 
patients that develop severe 
manifestations of COVID-19 (2.1, 
2.4).  
Fluid management: Cautious and 
conservative fluid management in 
severely ill patients is recommended 
and must be under direct guidance of 
an experienced physician. 
*Patients should be treated cautiously 
with intravenous fluids, because 
aggressive fluid resuscitation may 
worsen oxygenation, especially in 
settings where there is limited 
availability of mechanical ventilation 
(2.1, 2.4) 
Anti-microbials: Empiric use of 
antibioticsmaybe considered when 
bacterial superinfection (Bacterial 
Sepsis/pneumonia) is being suspected 
based on clinical judgement (high 
index of suspicion). In such a case, 
give appropriate, empiric broad-
spectrum antimicrobials as soon as 
possible following laboratory 
confirmation of causative organisms 
from respiratory and/ or blood 
samples.  
*Amoxicillin/ Clavulanic acid and 
Metronidazole combination for patient 
who can take oral medication is the 
first line antibiotic to consider.  
*Where oral medication is not 
feasible, give IV ceftriaxone and 
monitor for clinical improvement.  
*Empiric antibiotic treatment should 
be based on the clinical diagnosis 
(community acquired pneumonia, 
health care-associated pneumonia [if 
infection was acquired in health care 
setting] or sepsis), local epidemiology 
and susceptibility data, and treatment 
guidelines. 
*Empiric therapy should be de-
escalated on the basis of microbiology 
results and clinical judgment (2.1, 2.4, 
2.5).  
Anti-viral : There are no known 
effective antivirals for coronavirus 
infections and multiple clinical trials 
are ongoing to evaluate the activities 
of various antivirals in COVID-19 
(2.5).  
Bronchodilator : If bronchodilator 
treatment is required, provide metered 
dose inhalers and spacers instead of 
nebulizers to prevent aerosolization of 
the virus (2.1, 2.4, 2.6). 
. 
Nutritional Support  
*Consider medical nutrition therapy 
for all patients staying in the ICU, 
mainly for more than 48 hrs.  
*Oral diet shall be preferred over 
Enteral Nutrition or Parenteral 
Nutrition in critically ill patients who 
are able to eat, and if not possible, 
initiate early enteral nutrition within 
48 hours.  
*In case of contraindications to oral 
and Enteral Nutrition, Parenteral 
Nutrition should be initiated within 
three to seven days  
*Gastric access should be used as the 
standard approach to initiate Enteral 
Nutrition using nasogastric tube 
feeding  
*Hypocaloric nutrition (not exceeding 
70% of Estimated Energy) should be 
administered in the early phase of 
acute illness and increased from day 3 
to day 7 to 80-100% based on stability 
and tolerance of the patient.  
*Micronutrients (i.e. trace elements 
and vitamins) should be provided 
daily with Parenteral Nutrition and 
should be included for better recovery.  
*In non-intubated patients not 
reaching the energy target with an oral 
diet, oral nutritional supplements 
should be considered first and then 
Enteral Nutrition (2.1, 2.4).  
Energy  
*Critically ill adult patients should 
receive feedings at rates of 25 to 30 
kcal/kg.  
*The amount of glucose (PN) or 
carbohydrates (EN) administered to 
ICU patients should not exceed 5 
mg/kg/min.  
*For intravenous lipids the upper 
recommendation is 1 g/kg body 
weight/day with a tolerance up to 1·5 
g/kg/day (2.1, 2.4).  
Protein  
*For the unstressed adult patient with 
adequate organ function requiring 
nutrition support, 1.3 g/kg/day to 
1·5g/kg/day may be adequate.  
*Requirements may rise with 
metabolic demands to levels of about 
2 g/kg/day (2.1, 2.4)..  
 
Providing Psychological support: Staff 
should introduce self and the facility. 
Be sensitive to culture, ethnicity, 
gender, sexuality, and maintain a safe 
distance (2 metres). Be empathetic. 
Build a therapeutic relationship. 
Briefly highlight the services provided 
by the treatment centre (isolation of 
suspected cases and contacts, 
treatment of confirmed cases). Explain 
in clear terms the need for isolation 
and the use of PPE. Assess and 
respond to emotional reactions. 
Recognize cognitive coping strategies 
e.g. denial, blame, intellectualization. 
Explore what the news means to the 
patient. Offer realistic hope/optimism. 
Establish measures to reduce the 
negative impact of social isolation in 
quarantine e.g. communication with 
family and friends to reduce loneliness 
and psychological Isolation. Institute 
measures that promote autonomy (e.g. 
choice in daily activities). Offer 
complete assessment at admission. If 
there are mental health needs, request 
for a mental health assessment and 
care (2.1, 2.3, 2.4).  
 
a) Psychological First AID (PFA) 
(pages 28-29) 
This is a humane, supportive and 
practical help offered to those 
suffering serious crisis/ distressing 
events. PFA strives to provide and 
share accurate information that can 
help in dispelling myths and provides 
messages about healthy behaviour and 
better knowledge on people’s 
understanding of the COVID-19 
disease. PFA is provided to all persons 
diagnosed with COVID-19 by 
applying the main principles of Look, 
Listen, and Link (2.2,2.7) 
 
b) Health Education:  
Assess the knowledge of patient. 
Speak frankly, but compassionately. 
Avoid euphemisms and medical 
terms. Allow silence and tears. Avoid 
the urge to talk to avoid your own 
discomfort. Proceed at the patient’s 
pace. Have the patient tell you his or 
her understanding of what you have 
said. Encourage questions. Encourage 
and validate emotions (2.1, 2.3).  
 
c) Emotional support: 
Use of detailed and extensive 
psychoeducation; cognitive 
restructuring; active listening; seek for 
clarification; reflect on thematic issues 
discussed during the health talk and 
counselling session. Summarize 
discussions and provide feedback 
during session (2.1, 2.4, 2.8).  
 
d) Spiritual support:  
Provide Spiritual Support on request 
by the patient. Link patient with a 
well-informed spiritual leader. 
Interaction should be supervised by 
the counsellor at the treatment center 
(2.8) 
 
e) Psychiatric support:  
For all patients who manifest 
psychiatric symptoms, a trained 
Psychiatrist should evaluate and offer 
treatment options appropriate for the 
patient. The mhGAP-HIG approach is 
recommended. Treatment modalities 
are: Supportive Psychotherapy and 
Cognitive Restructuring. Use of 
medications only when necessary (to 
be prescribed by a trained healthcare 
worker). Conduct regular review and 
mental state monitoring 2.1, 2.4, 2.7).  
 
Evaluation at discharge and post 
discharge: Assess the patient’s 
psychosocial stability through clinical 
interview and formal assessment tools. 
Assess social needs and available 
resources. Assess occupational needs 
and available resources (2.1, 2.4) 
  
Post Discharge: Evaluate worry about 
stigma and coping Skills. Discourage 
maladaptive coping skills e.g. social 
withdrawal, misuse of alcohol and 
psychoactive substances. Help patient 
and relatives plan social and 
occupational reintegration (involve the 
social workers). Discuss the plan for 
home visit (if applicable) and future 
contact. The Oslo Social Support 
Scale should be administered to assess 
for social support at home. (See 
reference). Explore for symptoms of 
post-trauma and treat if present (2.1, 
2.4, 2.16).  
 
Support to survivors: A survivor 
network (where possible) should be 
established in conjunction with the 
treatment centres. Engage peer 
educators (if available) to facilitate 
group counselling. Provide testimony 
with the aim of inspiring others. Share 
coping skills (2.1, 2.4).  
 
Management of COVID-19 in Special 
Populations (pages 18-19) 
 
a) Pregnant and breastfeeding women 
with COVID-19  
*Presently, there is paucity of data on 
clinical presentation and perinatal 
outcomes after COVID-19 infection 
during pregnancy.  
*There is no evidence that pregnancy 
increases the risk of severe illness or 
that pregnant women present with 
different sign and symptoms.  
*There is no evidence yet of mother-
to-child transmission reported.  
*Just like the general population, 
pregnant women with history of 
contact should be monitored closely.  
*Suspected, probable or confirmed 
case should be provided with 
appropriate services: Isolation, 
obstetric, maternal, foetal and 
neonatal care  
*Pregnant women presenting as mild/ 
moderate, severe and critical cases 
should be managed as generically 
described above. A multidisciplinary 
approach must be adopted with 
consultations from obstetricians, 
paediatricians and intensive care 
experts.  
* IPC measures also apply to pregnant 
and breastfeeding women.  
*For pregnant women who are 
recovering from COVID-19 infection, 
psychosocial support  
and counselling should be provided.  
*Assessment of patient’s co-morbid 
condition(s) must be conducted, and 
management tailored accordingly 
(2.11) 
 
b) Infant & Mother with COVID-19  
*No vertical transmission has been 
reported (During pregnancy, birth and 
breastfeeding)  
*Infants whose mothers are suspected 
or confirmed COVID-19 patients 
should be breastfed according to the 
infant feeding guidelines while 
maintain necessary precautions for 
IPC. (Wear mask, hand hygiene 
before and after contact with infant, 
disinfect surfaces the mother may 
have come in contact with.  
*If the mother presents with severe 
illness, or other complications prevent 
her from direct breastfeeding, she 
should be encouraged to express milk. 
(must maintain IPC measures)  
*Breastmilk substitutes, feeding 
bottles and teats, pacifiers or dummies 
is not  recommended.  
*Encourage mother-baby-pair to 
remain together regardless of if 
mother or child is a suspect, probable 
or confirmed COVID-19 infection 
(2.11). 
 
c) Elderly patients with COVID-19  
*Comorbidities and old age have been 
reported as risk factors for mortality 
with people with COVID-19.  
*Elder people are at higher risk of 
severe illness and death if infected.  
*Manage such patients with a 
multidisciplinary approach especially 
in the decision-making process to 
address multiorgan involvement and 
clinical deterioration.  
*Also involve caregivers and family 
members in the decision-making 
throughout the management of the 
patient (2.1, 2.3, 211). 
 
d) People Living with HIV (PLHIV)  
*There are no data or specific 
information on the risk of COVID-19 
in PLHIV.  
*There is a suggested risk amongst 
PLHIV who are not on ART (yet to 
start) and those not adhering to ART 
(started but non-adherent to ART) 
(2.11). 







Yes Early supportive therapy and 
monitoring (page 5) 
*Give supplementary oxygen therapy 
immediately to patient with SARI and 
respiratory distress, hypoxia, or shock 
(2.4) 
*Use conservative fluid management 
in patients with SARI when there is no 
















































































*Give empirical antimicrobials to treat 
all likely pathogens casing SARI. 
Give antimicrobials within one hour 
of initial patient assessment for 
patients with sepsis (2.4, 2.5) 
*Don’t routinely give systemic 
corticosteroids for treatment of viral 
pneumonia or ARDS outside of 
clinical trials unless they are indicated 
for another reason (2.4, 2.6) 
*Closely monitor patients with SARI 
for signs of clinical deterioration, such 
as rapidly progressive respiratory 
failure and sepsis and apply 
supportive care interventions 
immediately (2.1, 2.2, 2.4) 
*Understand the patient co-morbid 
condition/s to tailor the management 
of critical illness and appreciate the 
prognosis. Communicate early with 
patient and family (2.4, 2.3, 2.1) 
 
Management of hypoxemic 
respiratory failure and ARDS (page 6) 
* Recognize severe hypoxemic 
respiratory failure when a patient with 
respiratory distress is failing standard 
oxygen therapy (2.4) 
*Endotracheal intubation should be 
performed by a trained and 
experienced provider using airborne 
precautions (2.4) 
*Implement mechanical ventilation 
using lower tidal volumes (4-8 ml/kg 
predicted body weight PBW) and 
lower inspiration pressure (plateau 
pressure ฀ 30 cmH2O) (2.4) 
*In patient with severe ARDS, prone 
ventilation for more than 12 hours per 
day is recommended (2.4) 
*Use a conservative fluid 
management strategy for ARDS 
patients without tissue hypo perfusion 
(2.4) 
 
Management of septic shock (page 6) 
*Recognize septic shock in adult 
when infection is suspected or 
confirmed and vasopressors are 
needed to maintain MAP ฀ 65mmHg 
and lactate ฀ 2mmol/L in absence of 
hypovolemia and in children with any 
hypotension or 2 to 3 of the following: 
altered mental state, tachycardia or 
bradycardia, tachypnea, oliguria, 
hyperthermia, hypothermia, mottled 
skin or petechial or purpuric rash (2.4, 
2.11) 
*In resuscitation from septic shock in 
adult give at least 30ml/kg isotonic 
crystalloid in the first 3 hours, and in 
children give 20ml/kg as a rapid bolus 
and up to 40-60 ml/kg isotonic in the 
first 1 hour (2.4, 2.5, 2.11) 
*Administer vasopressin when shock 
persists during or after fluid 
resuscitation, the initial blood pressure 
target is MAP ฀ 65mmHg in adults 
and age appropriate targets in children 
(2.4) 
 
Special consideration for pregnant and 
lactating women (page 7) 
*For pregnant women suspected of 
COVID-19 or confirmed and due for 
labor, to deliver in isolation centers 
(2.4, 2.11) 
*Isolation centers should be equipped 
with a surgical setup 
*If operation room not available, 
deliver in nearest facility and 
adherence to infection control 
measures 
*Lactating mothers should continue to 
breastfeed her infant/young child 
while taking all infection prevention 
precautions (2.4, 2.11) 
*If condition of mother deteriorates 
then separate child from mother and 
extract breast milk for feeding 
infant/young child (2.4, 2.11) 
*A midwife should be present in 
every isolation center 
*A nutritionist should be present in 
every isolation center 
Nutritional guideline during the 
isolation period for children age 6-59 
months (page 7 to 8) 
*Severe Acute Malnutrition (SAM), 
should apply SAM protocol for 
treatment (2.4, 2.11) 
*Moderate Acute Malnutrition 
(MAM), should apply MAM protocol 
for treatment 
*Child without Acute Malnutrition, 
should be provided Vitamino/plumpy 
doz 
*Healthy children without 
malnutrition should give one 
preventive dose of Vitamin (A), if 
she/he did not take any dose during 
the previous six months (2.4, 2.11) 
 
Additional Supportive Measures (page 
13) 
*Optimize nutritional support 
*Rationalize medications and guard 
against interactions (2.6) 
*VTE risk assessment and appropriate 
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No   COVID-19 management approach 
(page 14 to 19)        ▪Prioritised care 
including oxygen therapy should be 
offered to patients with severe acute 
respiratory infections. (2.1, 2.4) 
▪Case management focal point to call 
the patient and explain the procedures 
to be taken and allay anxiety among 
close relatives living with the patient 
(2.1, 2.3, 2.7) 
▪Patient should be provided with 
symptomatic treatment (e.g. 
Paracetamol for fever) (2.4) 
▪Consider hospitalization if the client 
is at high risk for severe disease (e.g. 
>60 years or pre-existing co-
morbidities including diabetes 
mellitus, hypertension, heart or lung 
disease) (2.1) 
▪Give empiric antimicrobials to cover 
both typical and atypical causes of 
Pneumonia within 1 hour of initial 
patient assessment as per standard 
protocol (2.5) 
▪Consider the patient’s comorbidities 
and manage them concurrently. (2.6) 
▪ Physiological changes with age lead 
to declines in intrinsic capacity such 
as malnutrition, cognitive decline, 
depressive symptoms, and those 
conditions should be managed 
comprehensively. (2.11, 2.7) 
▪ Early detection of inappropriate 
medication prescriptions is 
recommended to prevent adverse drug 

















































































▪ Involve caregivers and family 
members in decision-making and 
goal-setting throughout the 
management of COVID-19. (2.3, 2.14, 
2.17) 
▪Provide patient-centred support for 
patients currently not taking treatment 
or if struggling with adherence. (HIV) 
(2.1) 
 
Handling Dead Bodies (page. 26) 
▪The dignity of the dead, their cultural 
and religious traditions, and their 
families should be respected and 
protected throughout. (2.16, 2.9) 
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Management of severe cases (page 12 
to 13) 
*Provide supplemental O2 to achieve 
O2 sats >93%  (2.1, 2.4). 
*May deteriorate rapidly: 
continuously monitor O2 sat and vital 
signs; escalate oxygen dose and 
delivery devise if hypoxia remains 
with maximal oxygen doses (2.1) 
*Provide basic care of severe/critical 
illness:  
o A:maintain an openairway. If low 
conscious level–nurse patient in 
recovery position notlying flat-on-
back. Insert oro-pharyngeal airway if 
needed. Suction if airway secretions. 
o B: nurse in sitting up position. 
Provide simple chest physio. 
o C: give IV or NG fluids for shock 
o Supportive care – turn unconscious 
patients regularly. Provide adequate 
nutrition and pain relief  
* Non-invasive positive pressure 
ventilation is NOT recommended as it 













































































spread. If additional respiratory 
support is required, patients should be 
intubated (2.1, 2.4).  
*Begin arranging for transfer to higher 
level of care as needed (2.2). 
 
Management of critical cases (page 13 
to 14) 
*Provide basic care of severe/critical 
illness: 
o A: maintain an open airway. If low 
conscious level–nurse patient in 
recovery position notlying flat-on-
back. Insert oro-pharyngeal airway if 
needed. Suction if airway secretions. 
o B: nurse in sitting up position. 
Provide simple chest physio. 
o C: give IV or NG fluids for shock 
o Supportive care – turn unconscious 
patients regularly. Provide adequate 
nutrition and pain  
Relief (2.1, 2.4). 
*Test and treat co-infections, if 
possible, including influenza or other 
viruses, malarial blood tests, and 
blood cultures (2.4, 2.5). 
*Ventilator triage will likely be 
necessary  
o If resources are limited, determine 
which patients have the best chance of 
survival with mechanical ventilation 
(2.1). 
*End of life discussions should be 
held with patients and their families if 
resources are not available or 
appropriate, especially the elderly, 
terminally ill, and co-morbid with 
poor baseline functioning (2.3, 2.12). 
 
Psychosocial Team and support (page 
22 to 26) 
The psychosocial team is composed of 
Social Workers, Social Welfare 
Officers, Clinical and Community 
Psychologists, Risk Communication 
and Health Promotion experts, Charity 
Social care organization 
representatives, Community 
Development Officers and Psychiatric 
Medic such as Clinical Officer and 
Nurses.(2.16) The following are the 
roles of the psychosocial team during 
and after COVID outbreak:  
*Reaching out to communities in 
order to identify affected people, and 
those who are vulnerable, address 
social stigma and discrimination, 
neglected people and provide 
Psychosocial support to the affected 
people in all social and psychological 
needs (2.7) 
*Assessing affected people for 
psychological conditions and advise 
or link them to treatment interventions 
(2.1, 2.4, 2.7) 
*Enhancing psychosocial wellbeing of 
affected people and health workers on 
the task force (2.7, 2.17) 
*Networking with other service 
providers for psychosocial care of 
people (2.2,2.7, 2.16) 
*Communicating with other 
institution for supporting families of 
affected individuals (social service 
needs or material support) (2.2,2.7, 
2.16,2.17) 
*Engaging other social welfare 
structures to facilitate restoration of 
livelihood activities in post epidemic 
phase. (2.2,2.7, 2.16,2.17) 
*Training of frontline healthcare 
workers, community health workers 
and other responders in first 
psychological aid and risk 
communication (2.3) 
 
SOPs for Psychosocial Support to 
COVID Taskforce Health Workers 
Working In COVID Outbreak (2.17') 
In order to provide psychosocial 
support to COVID healthcare workers, 
it is recommended to follow this 
guidance before, during and after 
deployment of teams, in conjunction 
with the SOPs “Health Workers’ 
Occupational Safety and Health 
Management in the Context of 
COVID-19.  
Before deployment  
*Perform psychological evaluation of 
each healthcare worker, as part of the 
pre-deployment health check, ensure 
they are well informed of terms and 
conditions, possible occupational 
health and safety risks.  
* Provide psychosocial awareness 
among the taskforce members about 
nature of illness, signs and symptoms, 
mode of spread and case fatality.  
*Discuss with and train them on what 
medical and occupational health 
preparations they need to make/have 
in place and ask whether they are 
confident in use (PPEs, immunization, 
prevention of violence, fatigue, first 
psychological aid, buddy systems,  
*Ensure that heath care workers are 
informed of the emotional issues 
associated with the kind of work they 
are going for  
*Orient the team on self-help 
mechanisms needed to manage stress 
and relaxation methods, stimulating 
health-promoting coping strategies 
(sufficient rest, healthy food, physical 
activity, stay in contact with family 
and friends, relax and distress, first 
psychosocial aid, buddy systems) and 
avoiding unhealthy family, e.g. avoid 
wearing uniform in public, avoid 
bringing working clothes at home, 
digital connection  
with loved ones  
*Inform health workers about their 
rights and responsibilities as 
humanitarian workers 10)Specific 
attention should be paid to repurposed 
health workers, i.e. medical and 
nursing students, volunteers, other 
health workers which don’t have 
previous experience in working under 
public health emergencies and 
providing patient care to patients with 
infectious diseases and using PPE  
During deployment  
*Arrange sessions (once weekly) for 
healthcare workers to voluntarily 
attend and share COVID experiences 
2) Discuss with the healthcare workers 
on how to enhance coping 
mechanisms and to maintain a 
respectful working relation and 
encourage those with serious distress 
(if any) to seek medical or 
psychological care.  
*Work with the logistic team to 
ensure that health workers are availed 
with recreational facilities such as  
films and documentaries sharing 
COVID experiences especially for 
survivors 
*Ensure there are mechanism for 
deployed health workers to contact 
their families (loved once) while you 
promote team work among them and 
clear definitions of tasks, 
responsibilities and reporting lines 
*Always be sure that social issues for 
health workers are all addressed for 
them to improve their working 
environment 
*Explain how to deal with stigma or 
fear against health workers in the 
community,  workplace, and violence 
against health workers and social 
support  
After deployment  
*Psychosocial personnel must 
evaluate the level of distress/worries 
about exposure and conduct stress 
management session to the workers  
*Encourage positive self-talk, attitude 
and disclosure to treatment in case the 
health workers are suspecting 
contracting COVID.  
*Ensure that fellow staff are provided 
with appropriate time for moment of 
grieving  
*Arrange through Clinical Psychiatrist 
to conduct medical evaluation using 
standard tools for health workers 
coming back from COVID mission  
*Refer to mental health care, as 
appropriate, all cases of mental health 
disorders and substance abuse, caused 
by or aggravated by the work in 
emergency response  
 
When providing psychosocial support 
to individuals, families, rejected 
persons and community members 
follow these steps:  
*Interact with the client but avoid 
direct contact. Establish 
rapport/alliance.  
*Promote active listening to the client 
and show that you are willing to offer 
help to them while expressing 
empathy, using open-ended questions 
and understandable language.  
*Client must be provided with 
adequate information to counteract 
false beliefs about the disease and told 
that anxiety is a common reaction in 
the face of extreme situations like 
what they are going through. (2.3) 
*Promote positive thinking among 
community members at risk, stress 
management and relaxation 
techniques, encourage healthy eating 
and drinking habits as recommended 
by medical experts. (2.7) 
*During confinement, allow contact to 
connect with their social networks 
either by phone or through alternative 
safe approaches (2.3, 2.7) 
*When connecting COVID contacts to 
their social networks or spiritual 
support ensure that client’s social 
network (family members and 
significant others) are oriented about 
COVID and safety precautions before 
linking with the client. (2.7, 2.8) 
*Encourage family members to 
regulate their emotions before contact 
with client and provide necessary 
support through the available safety 
procedures. (2.7, 2.17) 
*When preparing COVID 19 
survivors before discharge, follow the 
following steps: 
. Provide Psychosocial support (PSS) 
with survivor’s family, neighbourhood 
and community members to avoid 
discrimination and stigmatization for 
individual and family member at the 
community level.  
. Talk to the survivor about anticipated 
stigma, and stress. Equip them with 
stress management skills. (2.7) 
*When communicating death to the 
family members after confirmation of 
death from case management team, it 
is advised to the psychosocial team to 
follow the following steps:  
. Contact and invite family members 
of the deceased to witness the body of 
their relative.  
. Communicate the death of their 
beloved one, the time he died, the 
cause of death (use  
laboratory results) and burial 
arrangements  
. In case of a very ill relative to the 
deceased within the Treatment Unit 
the psychosocial team will consider 
their health state to or not to 
communicate information about the 
death of a  
beloved one.  
. In case the very sick relative is aware 
of the death of a close relative within 
the Treatment Unit , support the 
person in grief process.  
. Discuss with family member about 
alternative ritual practices and safe 
mourning. (2.3, 2.13, 2.17) 
Togo  Protocole de 
prise en charge 
thérapeutique 
des  
cas de Covid -












Yes 5.4 Treatment for symptoms and 
complications 
- Paracetamol 1000 mg every 8 hours 
in case of fever (2.4) 
Reduce throat pain with lemon and 
honey (2.10) 
- Oral rehydration / 3 liters per day 
- Vitamin C 1 tablet per day 
- Amoxicillin and clavulanic acid or 
ceftriaxone if lung infection (2.5) 
- Anti histamine like (desloratadine, 
loratadine, mequitazine) if cold 
-Oxygen therapy in case of dyspnea 
with respiratory rate greater than 30 
cycles per minute and or a pulse 
oxygen saturation lower at 92% (the 
flow must be set to have a saturation ≥ 
92%). (2.1, 2.4) 
For oxygen therapy, use: 
Glasses for flow rates between 1 and 5 
liters/min 
Masks for flow rates from 6 to 10 
liters per minute 
o Mask at high concentration for flow 
rates greater than 10 liters per minute 
-Ventilation assistance to be 
considered if persistence of 
respiratory distress with lower 
saturation 90% despite oxygen 

















































































No date and no 
version 
Yes Management of severe COVID-19 
(Page 22)                                                        
•Give supplemental oxygen therapy 
immediately to patients with SARI 
and respiratory distress, hypoxaemia 
or shock and target > 94% and ≥ 92–
95% in pregnant patients . 
• Closely monitor patients with 
COVID-19 for signs of clinical 
















































































progressive respiratory failure and 
sepsis and respond immediately with 
supportive care interventions. (2.1, 
2.2) 
• Application of timely, effective and 
safe supportive therapies is the 
cornerstone of therapy for patients that 
develop severe manifestations of 
COVID-19. (2.1) 
• Understand the patient’s co-morbid 
condition(s) to tailor the management 
of critical illness. (2.1) 
• Monitor for drug-drug interactions. 
(2.6) 
• Use conservative fluid management 
in  Septic shock (page 26 to 27)  
• Recognize septic shock in adults 
when infection is suspected or 
confirmed AND vasopressors are 
needed to maintain mean arterial 
pressure (MAP) ≥ 65 mmHg AND 
lactate is ≥ 2 mmol/L, in absence of 
hypovolemia. 
• Recognize septic shock in children 
with any hypotension (systolic blood 
pressure [SBP] < 5th centile or > 2 SD 
below normal for age) or two or more 
of the following: altered mental state; 
tachycardia or bradycardia (HR < 90 
bpm or > 160 bpm in infants and HR < 
70 bpm or > 150 bpm in children); 
prolonged capillary refill (> 2 sec) or 
feeble pulses; tachypnea; mottled or 
cold skin or petechial or purpuric rash; 
increased lactate; oliguria; 
hyperthermia or hypothermia  
• In resuscitation for septic shock in 
adults, give at 250–500 mL crystalloid 
fluid as rapid bolus in first 15–30 
minutes and reassess for signs of fluid 
overload after each bolus. 
• In resuscitation from septic shock in 
children, give 10–20 mL/kg 
crystalloid fluid as a bolus in the first 
30–60 minutes and reassess for signs 
of fluid overload after each bolus. 
(2.1, 2.4) 
• Monitor for overload                            
Caring for Pregnant women with 
COVID-19 (page 28) 
• Considering asymptomatic 
transmission of COVID-19 may be 
possible in pregnant or recently 
pregnant women, as with the general 
population all women with 
epidemiologic history of contact 
should be carefully monitored. 
• Pregnant women with a suspected, 
probable or confirmed COVID-19 
infection, including women who may 
need to spend time in isolation with 
obstetric, foetal medicine and neonatal 
care, as well as mental health and 
psychosocial support, with readiness 
to care for maternal and neonatal 
complications. 
• At this point, there is no evidence 
that pregnant women present with 
increased risk of severe illness or fetal 
compromise. 
•Pregnant and recently pregnant 
women who have recovered from 
COVID-19 should be enabled and 
encouraged to attend routine antenatal, 
postpartum or post-abortion care as 
appropriate. patients with SARI when 
there is no evidence of shock (2.11).                                                                
Treatment of co-infections (page 23)     
• Give empiric antimicrobials to treat 
all likely pathogens causing SARI and 
sepsis as soon as possible, within 1 
hour of initial patient assessment for 
patients with sepsis (2.5). 
• Empiric therapy should be de-
escalated on the basis of microbiology 
results and clinical judgment.                                              
Acute Respiratory Distress Syndrome 
(page 24)                                    
•Recognize severe hypoxemic 
respiratory failure when a patient with 
respiratory distress is failing standard 
oxygen therapy and prepare to provide 
advanced oxygen/ventilatory support. 
(2.1) 
• Endotracheal intubation should be 
performed by a trained and 
experienced provider using airborne 
precautions. 
• Rapid sequence intubation is 
appropriate after an airway assessment 
that identifies no signs of difficult 
intubation .                                         
Caring for Infants and Mothers with 
COVID-19 (page 29) 
• Infants born to mothers with 
suspected, probable or confirmed 
COVID-19 infection, should be fed 
according to standard infant feeding 
guidelines, while applying necessary 
precautions for IPC (2.11). 
• As with all confirmed or suspected 
COVID-19 cases, symptomatic 
mothers who are breastfeeding or 
practicing skin-to-skin contact or 
kangaroo mother care should practise 
respiratory hygiene, including during 
feeding (for example, use of a medical 
mask when near a child if with 
respiratory symptoms), perform hand 
hygiene before and after contact with 
the child, and routinely clean and 
disinfect surfaces which the 
symptomatic mother has been in 
contact with. 
• Breastfeeding counselling, basic 
psychosocial support and practical 
feeding support should be provided to 
all pregnant women and mothers with 
infants and young children, whether 
they or their infants and young 
children have suspected or confirmed 
COVID-19. 
• In situations when severe illness in a 
mother due to COVID-19 or other 
complications prevent her from caring 
for her infant or prevent her from 
continuing direct breastfeeding, 
mothers should be encouraged and 
supported to express milk, and safely 
provide breastmilk to the infant, while 
applying appropriate IPC measures 
Caring for Older Persons with 
COVID-19 (pg 30)  
• Ensure multidisciplinary 
collaboration among physicians, 
nurses, pharmacists, other health care 
professionals in the decision making 
process to address multi morbidity and 
functional decline (2.16). 
• Early detection of inappropriate 
medication prescriptions is 
recommended to prevent adverse drug 
events and drug interactions for those 
being treated with COVID-19 (2.6). 
• Involve caregivers and family 
members in decision-making and 
goal- setting throughout the 
management of COVID-19 (2.1, 2.3, 
2.14) 
Legend 
Standard 2.1: Planning and Coordination of Care 
Standard 2.2: Access to Care 
Standard 2.3: Communication in palliative care  
Standard 2.4: Pain and Symptom Management 
Standard 2.5: Management of Opportunistic Infections (OIs) 
Standard 2.6: Management of Medications 
Standard 2.7: Psychosocial Care  
Standard 2.8: Spiritual Care 
Standard 2.9: Cultural Care 
Standard 2.10: Complementary therapies in palliative care 
Standard 2.11: Care for special needs populations 
Standard 2.12: End-of-life care 
Standard 2.13: Grief, loss and bereavement care in adults 
Standard 2.14: Ethical care, human rights and legal support 
Standard 2.15: Clinical Supervision 
Standard 2.16:  Inter-disciplinary Team  
Standard 2.17:   Providing support to care providers 
 
